All In Biotech

Drug Trial Radar · NCT06218030

Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

PSIY-744-23: Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 22, 2024

Primary completion

Apr 1, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
Queen's UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment. Secondary objectives are to compare the severity of symptoms, serum levels of folate, vitamin B12, C-reactive protein, homocysteine, tumor necrosis factor alpha and interleukin 6 before and after treatment. Participants will continue with their usual treatment for GAD and receive add on treatment with L-methylfolate 15 mg per day for 8 weeks. All participants will receive the same intervention.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • L-methylfolateDrug

    Oral administration of L-methylfolate 15 mg per day for 8 weeks. The study drug will be given in addition to the standard of care (SOC) for GAD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: Throughout the study, 8 weeks
  2. Incidence of treatment-emergent side effects measured with the ASECTime frame: Baseline visit, 4-week visit and 8-week visit.
  3. Response to treatment defined by CGI-I score below 3Time frame: 4-week visit and 8-week visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.